Head-To-Head Review: Trevi Therapeutics (NASDAQ:TRVI) vs. DNAPrint Genomics (OTCMKTS:DNAG)

Trevi Therapeutics (NASDAQ:TRVI) and DNAPrint Genomics (OTCMKTS:DNAG) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, risk, valuation, earnings and dividends.

Insider & Institutional Ownership

95.8% of Trevi Therapeutics shares are held by institutional investors. 18.3% of Trevi Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Earnings and Valuation

This table compares Trevi Therapeutics and DNAPrint Genomics”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Trevi Therapeutics	N/A	N/A	-$42.76 million	($0.32)	-35.41
DNAPrint Genomics	N/A	N/A	N/A	N/A	N/A

Analyst Recommendations

This is a summary of current ratings and price targets for Trevi Therapeutics and DNAPrint Genomics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Trevi Therapeutics	1	0	9	2	3.00
DNAPrint Genomics	0	0	0	0	0.00

Trevi Therapeutics currently has a consensus price target of $21.60, indicating a potential upside of 90.64%. Given Trevi Therapeutics’ stronger consensus rating and higher possible upside, analysts clearly believe Trevi Therapeutics is more favorable than DNAPrint Genomics.

Profitability

This table compares Trevi Therapeutics and DNAPrint Genomics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Trevi Therapeutics	N/A	-25.49%	-24.15%
DNAPrint Genomics	N/A	N/A	N/A

Volatility & Risk

Trevi Therapeutics has a beta of 0.94, meaning that its stock price is 6% less volatile than the S&P 500. Comparatively, DNAPrint Genomics has a beta of 0.11, meaning that its stock price is 89% less volatile than the S&P 500.

Summary

Trevi Therapeutics beats DNAPrint Genomics on 7 of the 9 factors compared between the two stocks.

About Trevi Therapeutics

Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER (CORAL) clinical trial for treatment of chronic cough in patients with IPF; phase 2a Refractory Chronic Cough Improvement Via NAL ER (RIVER) clinical trial for reducing chronic cough in RCC patients; phase 2 clinical trial in patients with pruritus; phase 2b/3 clinical trial in patients with prurigo nodularis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.

About DNAPrint Genomics

DNAPrint Genomics, Inc. engages in the development and marketing of genetic testing products and services. It offers AncestryByDNA, a pan-chromosomal assay for genetic ancestry; EurasianDNA, which measures European sub-ancestry; EuropeanDNA, which reports a customer’s proportional basic continental European ancestry; DNAWitness to determine genetic heritage from DNA samples obtained from crime scenes; RETINOME, which provides a physical portrait of a person of interest for a detective based on a DNA sample from a crime scene or remains of an individual; RETINOME, which allows infer eye color from DNA; and GenomeLab SNPstream Genotyping System, which offers genotyping rates and uses a multiplexing format to generate data with the minimum of reagents. The company serves forensic science, genealogical research, consumer products, and pharmaceutical development clients. DNAPrint Genomics, Inc. was formerly known as Lexington Energy, Inc. The company was incorporated in 1983 and is based in Sarasota, Florida with a subsidiary in Leverkusen, Germany.